[Therapeutic effects of hTR-siRNA adenovirus on human cervical cancer xenografts in nude mice].
OBJECTIVE
To study the anti-tumor effects and its mechanism of hTR-siRNA adenovirus on human cervical cancer in vivo.


METHODS
The in vivo model of human cervical cancer was established by the subcutaneous inoculation of HeLa cells at the right armpit of BALB/c nu/nu mice. After successful implantation, the mice were randomized into four groups, in which the mice were intratumorally injected with 0.1 mL of Ad-hTR-siRNA (10(13) pfu/L), or Ad-NT-siRNA (10(13) pfu/L), or Cisplatin (1.20 g/L), or serum-free DMEM alone respectively. These treatments were given once every 3 days for 6 times. After the last injection, the mice were observed for 7 days continuously and sacrificed at the end. The tumors were harvasted, weighed, and sectioned. The TUNEL assay was used to assess the apoptosis of these tumor cells.


RESULTS
Tumors-implanted were established successfully by 100% with HeLa cells. As compared with Ad-NT-siRNA, Ad-hTR-siRNA could slow down tumor growth, decrease tumor volume (45.48%) and tumor weight (34.68%), as well as promote the apoptosis and necrosis of tumor cells. The TUNEL positive cells were about 11.8%. But the anti-tumor activity of Ad-hTR-siRNA didn't catch on Cisplatin's.


CONCLUSIONS
This study indicated that the hTR-siRNA adenovirus could suppress cervical cancer-xenografted growth in vivo and induce tumor cell apoptosis or necrosis.
Li
Wan-yi
WY
Department of Microbiology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, China.
Li
Ming-yuan
MY
Xiao
Li-ying
LY
Zhang
Chao-liang
CL
Liu
Yu-rong
YR
Li
Xiao-yu
XY
Zhang
Si-yuan
SY
Li
Yan
Y
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000235:genetics; D006367:HeLa Cells; D006801:Humans; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D012313:RNA / Q000037:antagonists & inhibitors* / Q000235:genetics; D034741:RNA, Small Interfering / Q000235:genetics / Q000627:therapeutic use*; D019098:Telomerase / Q000037:antagonists & inhibitors* / Q000235:genetics; D002583:Uterine Cervical Neoplasms / Q000628:therapy*
D034741:RNA, Small Interfering; C422952:telomerase RNA; D012313:RNA; D019098:Telomerase